Triple meeting 2024 – can Revolution succeed where others stumbled?
The group will present the first clinical data on its KRAS G12D-selective project RMC-9805.
Ipsen casts doubt on Pfizer’s prostate plan
Mevrometostat is the only EZH2 inhibitor in phase 3 for prostate cancer.
The month ahead: October’s upcoming events
Approval decisions loom for Opdivo and Lumakras, and earnings season starts again.
Regor’s selective approach attracts Roche
For $850m up front Roche gets to challenge Pfizer.
